Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

This study is testing whether adding low-dose radiotherapy to a combination of immunotherapy (sintilimab) and chemotherapy before surgery improves outcomes in people with stage II–III non-small cell lung cancer (NSCLC). The goal is to shrink the tumor as much as possible before the operation. **You may be eligible if...** - You are 18 or older with newly diagnosed, surgically removable NSCLC (adenocarcinoma or squamous cell type) - Your cancer is stage IIB (tumor >4 cm), IIIA, or select IIIB - Your lung function is adequate for the planned surgery - You do not have EGFR or ALK gene mutations (required for non-squamous NSCLC) - You are in good health (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread beyond the lungs (distant metastases) - You have active autoimmune disease or are on systemic steroids - You have had prior lung cancer treatment - Your lung function is too low for surgery - You have known EGFR/ALK mutations (non-squamous type) Talk to your doctor to see if this trial is right for you.